Search This Blog

Wednesday, September 19, 2018

Mars aims to tackle ‘broken’ cocoa model with new sustainability scheme


Mars Wrigley Confectionery launched a new sustainability strategy on Wednesday with the aim of combating deforestation, child labor and poverty in what it called the “broken” cocoa supply chain.

U.S.-based Mars, the maker of M&Ms and Snickers, said it had revamped its cocoa strategy in an effort to tackle problems that the company and wider industry had so far failed to address.
“The cocoa supply chain as it works today is broken,” John Ament, global vice president of cocoa at the privately owned company, told Reuters in an interview.
“It’s time to recognize this and to build a new model and a new approach that focuses on putting the smallholder at the center.”
The cocoa industry’s current approach to sustainability has drawn criticism in recent months, as years of scattered actions have done little to improve the lives of farmers and prevent environmental degradation.
Under the new sustainability scheme – which will cost the company $1 billion over 10 years – all the cocoa it buys will be responsibly sourced by 2025, Mars said.
This means the cocoa will fit the company’s internal criteria – including full traceability to ensure it doesn’t contribute to deforestation – and carry a stamp of approval from a third-party verifier.
Mars had previously committed to buying 100 percent certified cocoa by 2020. However, the company is now looking to move “beyond certification”, which has not delivered the impact the company had hoped for, according to Ament.
“Certification isn’t enough,” he said. “Our belief is that we need to set more demanding standards than certification sets today.”
Currently, 50 percent of the cocoa that Mars buys is certified by schemes such as Rainforest Alliance and Fairtrade. Mars said it will maintain these volumes and potentially increase them if it sees improvements in the schemes’ standards.
Certification – designed to ensure more ethical practices and better earnings – has also been widely criticized as doing little to improve the lives of farmers, as the premiums they receive under the biggest of these schemes have been falling.
HIGHER PREMIUMS, GPS MAPPING
As part of its new scheme, Mars said it will work with certifiers and suppliers to “overhaul” its premium model, ensuring it pays more for responsibly sourced cocoa.
“We’ll see a combination of increased premiums overall and a bigger share of those premiums going to the farmers,” Ament said.
The scheme will also use GPS mapping to ensure none of the cocoa it sources is coming from protected forests. Much of the surge in production in West Africa has come from the encroachment of cocoa into protected areas.
Mars also plans to work with certifiers and suppliers to tackle hazardous child labor on plantations through community monitoring and intervention schemes.
However, the company said it recognizes that the voluntary nature of such program – coupled with limited access to schooling – poses a challenge. It aims to work with governments to drive investments in infrastructure and to provide communities with an alternative to child labor.
The company’s new strategy also involves measures aimed at ensuring long-term sustainability, which will be rolled out across 75,000 farming families and suppliers. These will aim to boost productivity, help producers diversify crops and improve access to finance.
“We’re convinced that these farmers need a broader source of income to ensure that they have a resilient model, with income spread throughout the year rather than just two peak seasons of cocoa,” Ament said.
Some critics have accused productivity schemes of contributing to overproduction, with Ivory Coast this year halting the distribution of higher-yielding seed varieties and other advanced tools.
However, Ament said Mars is seeking to collaborate with governments and stakeholders to ensure productivity increases do not have a negative impact on supply and price.

Delcath up 57% as end of subscription rights period approaches


Thinly traded nano cap Delcath Systems (DCTH +56.6%) is up on a 15x surge in volume, albeit on turnover of only 242K shares. The stock has doubled since last week.
The company’s subscription rights will be exercisable until 5:00 pm ET on September 26. Under the terms of the rights offering, stockholders will be entitled to purchase 500 common shares at $1.75 for each share owned. Holders who fully exercise their subscription rights will be have an oversubscription privilege subject to conditions.

Galera Therapeutics Nabs $150 Million to Drive Lead Therapeutic Into Phase 3


Privately-held Galera Therapeutics secured $150 million in a Series C funding round that will be used to drive its experimental head and neck cancer treatment GC4419 into Phase III trials, as well as support pre-commercialization activities.
In a Phase IIb clinical trial, GC4419 demonstrated significant reductions in the incidence and duration of radiation-induced severe oral mucositis (SOM) in patients with locally advanced head and neck cancer. Data showed that GC4419 was able to reduce the duration of SOM from 19 days to 1.5 days, a reduction of 92 percent. SOM is one of the most debilitating side effects of radiotherapy, and there are currently no effective therapies to prevent or mitigate it, the company said this morning.
GC4419 is a “highly selective and potent small molecule dismutase mimetic” that closely imitates the activity of human superoxide dismutase enzymes, according to company data. The experimental drug works to reduce elevated levels of superoxide caused by radiation therapy by rapidly converting superoxide to hydrogen peroxide and oxygen. Phase III is expected to be initiated in the fourth quarter of this year, the company noted.
The U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy designation to GC4419 for the reduction of the duration, incidence and severity of SOM induced by radiation therapy with or without systemic therapy. It was also granted Fast Track designation to GC4419 for the reduction of the severity and incidence of radiation and chemotherapy-induced oral mucositis.
Mel Sorensen, president and chief executive officer of Galera, said the $150 million Series C validates the “dramatic and meaningful results” of the Phase IIb trial.
“The funds provide Galera with ample financial resources to complete the Phase III clinical trial, begin commercial planning activities and further explore the potential of GC4419 beyond SOM. We look forward to initiating a supportive care trial of GC4419 in radiation-induced esophagitis and a therapeutic trial in a second cancer indication, as well as continuing to evaluate the safety and anti-tumor effect of GC4419 in our ongoing Phase I/II pancreatic cancer clinical trial,” Sorensen said in a statement.
Galera dosed the first patient in the pancreatic cancer trial in February.
The Series C funding round included a $70 million equity raise and an $80 million royalty financing payable from future sales. The round was supported by new investor Clarus, with participation from additional new investors Adage Capital Management, HBM Healthcare Investments, Nan Fung Life Sciences, RA Capital, Rock Springs Capital and Tekla Capital Management LLC. Existing investors Correlation Ventures, Galera Angels, New Enterprise Associates, Novartis Venture Fund, Novo Ventures and Sofinnova Ventures.
Under terms of the financing agreement, Emmett T. Cunningham, managing director of Clarus, will assume a seat on the Galera board of directors. Additionally, Clarus will receive single-digit future commercial royalties from the sales of GC4419 and a related pipeline asset until the total royalty amount achieves an undisclosed multiple of the initial $80 million, upon which the royalty terminates.
“With its highly differentiated scientific approach and its potential in a number of indications, GC4419 is well-positioned to address serious unmet medical needs. We’re pleased to support Galera as the company moves closer to potentially bringing GC4419 to head and neck cancer patients with SOM who need a new treatment option,” Cunningham said in a statement.

Centene initiated at MUFG


Centene initiated with an Overweight at MUFG. MUFG analyst Jason Twizell started Centene with an Overweight rating and $170 price target. The analyst sees an attractive risk/reward profile given the stock’s discount to peers. He believes Centene’s “significant” Medicaid and Medicare growth opportunities make the discount unwarranted.

Novocure price target raised to $58 from $53 at Wells Fargo


Wells Fargo analyst Larry Biegelsen raised his price target for Novocure to $58 ahead of the company’s September 25 data presentation from the Phase 2 Stellar study of Optune for mesothelioma. Positive top-line data already disclosed by Novocure shows that Optune added to current standard of care improves survival in mesothelioma patients, Biegelsen tells investors in a research note. The analyst expects FDA approval in 2019 and keeps an Outperform rating on shares of Novocure.

Pacira price target raised to $55 from $50 at RBC Capital


RBC Capital analyst Randall Stanicky raised his price target on Pacira to $55 and kept his Buy rating after meeting with its management, saying the discussion gave him more confidence about the company’s continued profitability momentum and more tailwinds coming in 2019. The analyst cites Pacira’s efforts to achieve a broader label for EXPAREL, expansion of its r Ambulatory Surgery Center presence, and the confidence that it will “receive a J-code for EXPAREL” on January 1st.

ChemoCentryx weakness a buying opportunity, says Canaccord


Canaccord analyst Michelle Gilson noted ChemoCentrx’s partner Vifor announced they increased their ownership stake in the company and she views it as a vote of confidence in its rare renal franchise. The analyst said the weakness overlooks the avacopan strong clinical data for AAV and she expects a broad uptake of the drug if Phase 3 is successful. Gilson reiterated her Buy rating and $18 price target on ChemoCentryx shares.